Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Enterprise/Commercial | 40.2 | 49.1 | 55.5 | 40.4 | 33.0 | |
| Medicare | 22.1 | 18.6 | 18.0 | 16.2 | 15.9 | |
| Private Exchange | 12.3 | 10.8 | 9.0 | 6.4 | 6.2 | |
| Enterprise/State | 2.1 | 3.5 | 13.4 | 21.6 | 3.2 | |
| Total revenues | 76.7 | 81.9 | 95.8 | 84.6 | 58.3 | 29.6 |
| Revenue growth [+] | -6.3% | -14.6% | 13.3% | 45.0% | 96.9% | |
| Enterprise/Commercial | -18.1% | -11.5% | 37.4% | 22.2% | | |
| Medicare | 19.0% | 3.3% | 11.1% | 1.5% | | |
| Private Exchange | 14.1% | 19.7% | 40.8% | 3.6% | | |
| Enterprise/State | -37.9% | -74.2% | -38.2% | 580.9% | | |
| Cost of goods sold | 47.1 | 56.9 | 50.7 | 52.4 | 50.2 | 22.9 |
| Gross profit | 29.7 | 25.0 | 45.2 | 32.1 | 8.2 | 6.7 |
| Gross margin | 38.7% | 30.5% | 47.1% | 38.0% | 14.0% | 22.8% |
| Selling, general and administrative [+] | 24.7 | 23.6 | 23.9 | 18.3 | 19.0 | 14.1 |
| Sales and marketing | 9.4 | 10.4 | 9.5 | 7.7 | 6.8 | 6.6 |
| General and administrative | 15.4 | 13.2 | 14.4 | 10.6 | 12.2 | 7.5 |
| Research and development | 16.7 | 22.3 | 22.7 | 18.1 | 11.8 | 7.4 |
| EBITDA [+] | -7.3 | -16.3 | 3.6 | 0.8 | -17.9 | -13.8 |
| EBITDA growth | -55.0% | -557.5% | 321.8% | -104.7% | 30.4% | |
| EBITDA margin | -9.5% | -19.9% | 3.7% | 1.0% | -30.7% | -46.4% |
| Depreciation | 1.0 | 1.2 | 1.0 | 1.0 | 0.9 | 1.0 |
| EBITA | -8.4 | -17.5 | 2.5 | -0.1 | -18.8 | -14.8 |
| EBITA margin | -10.9% | -21.3% | 2.6% | -0.1% | -32.2% | -49.8% |
| Amortization of intangibles | 3.4 | 3.4 | 4.0 | 4.1 | 3.9 | |
| EBIT [+] | -11.7 | -20.9 | -1.5 | -4.3 | -22.6 | -14.8 |
| EBIT growth | -43.8% | 1303.5% | -65.1% | -81.2% | 53.3% | |
| EBIT margin | -15.3% | -25.5% | -1.6% | -5.0% | -38.8% | -49.8% |
| Interest expense | 3.3 | 3.5 | 5.7 | 5.9 | 4.6 | 2.0 |
| Interest expense | 3.3 | 3.5 | 5.7 | 5.9 | 4.6 | 2.0 |
| Other income (expense), net | -0.5 | -2.2 | -0.1 | 0.1 | | |
| Pre-tax income | -15.5 | -26.6 | -7.3 | -10.1 | -27.3 | -16.8 |
| Income taxes | 0.0 | -0.1 | 0.1 | 0.0 | -0.9 | 0.0 |
| Tax rate | | 0.2% | | | 3.3% | 0.0% |
| Net income | -15.5 | -26.5 | -7.3 | -10.2 | -26.4 | -16.8 |
| Net margin | -20.3% | -32.4% | -7.7% | -12.0% | -45.2% | -56.6% |
| |
| Basic EPS [+] | ($0.68) | ($1.19) | ($0.34) | ($7.46) | ($143.35) | ($12.38) |
| Growth | -42.7% | 253.9% | -95.5% | -94.8% | 1058.3% | |
| Diluted EPS [+] | ($0.68) | ($1.19) | ($0.34) | ($7.46) | ($143.35) | ($12.38) |
| Growth | -42.7% | 253.9% | -95.5% | -94.8% | 1058.3% | |
| |
| Dividends per share [+] | | | | $6.60 | | |
| Growth | | | -100.0% | | | |
| |
| Shares outstanding (basic) [+] | 22.8 | 22.3 | 21.8 | 1.4 | 0.2 | 1.4 |
| Growth | 2.3% | 2.1% | 1501.4% | 640.1% | -86.4% | |
| Shares outstanding (diluted) [+] | 22.8 | 22.3 | 21.8 | 1.4 | 0.2 | 1.4 |
| Growth | 2.3% | 2.1% | 1501.4% | 640.1% | -86.4% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|